Claire Booth, M.B.,B.S., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Severe Combined Immunodeficiency | 5 | 2023 | 223 | 0.840 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2023 | 547 | 0.630 |
Why?
|
| Agammaglobulinemia | 4 | 2023 | 167 | 0.630 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 3 | 2020 | 260 | 0.560 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 13 | 2023 | 5442 | 0.550 |
Why?
|
| Adenosine Deaminase | 5 | 2023 | 241 | 0.520 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2022 | 523 | 0.450 |
Why?
|
| Granulomatous Disease, Chronic | 2 | 2020 | 174 | 0.320 |
Why?
|
| Lentivirus | 2 | 2021 | 501 | 0.300 |
Why?
|
| Antigens, CD34 | 2 | 2020 | 657 | 0.280 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 2866 | 0.190 |
Why?
|
| Sexual Development | 1 | 2020 | 34 | 0.180 |
Why?
|
| Urogenital System | 1 | 2020 | 86 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2915 | 0.180 |
Why?
|
| Transplantation Conditioning | 4 | 2020 | 1598 | 0.180 |
Why?
|
| Antigens, CD | 1 | 2010 | 4026 | 0.180 |
Why?
|
| Chromosomes, Human, X | 1 | 2020 | 296 | 0.160 |
Why?
|
| Urogenital Abnormalities | 1 | 2020 | 261 | 0.150 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2017 | 29 | 0.150 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 2957 | 0.140 |
Why?
|
| Genetic Vectors | 2 | 2021 | 3420 | 0.120 |
Why?
|
| Child, Preschool | 12 | 2021 | 41006 | 0.120 |
Why?
|
| Infant | 10 | 2023 | 35136 | 0.110 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 594 | 0.110 |
Why?
|
| Child | 14 | 2023 | 77709 | 0.100 |
Why?
|
| Mutation | 4 | 2020 | 29786 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2019 | 2421 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2018 | 2440 | 0.090 |
Why?
|
| DNA Repair | 1 | 2017 | 2046 | 0.080 |
Why?
|
| Adolescent | 10 | 2021 | 85781 | 0.070 |
Why?
|
| Transplantation, Homologous | 2 | 2022 | 4776 | 0.070 |
Why?
|
| Phenotype | 2 | 2020 | 16365 | 0.070 |
Why?
|
| Herpesvirus 4, Human | 1 | 2010 | 1041 | 0.060 |
Why?
|
| Lymphocyte Count | 2 | 2021 | 793 | 0.060 |
Why?
|
| Infant, Newborn | 5 | 2023 | 25625 | 0.060 |
Why?
|
| Treatment Outcome | 8 | 2023 | 63114 | 0.060 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2010 | 570 | 0.060 |
Why?
|
| Siblings | 2 | 2022 | 854 | 0.060 |
Why?
|
| Alleles | 3 | 2020 | 6933 | 0.060 |
Why?
|
| Young Adult | 6 | 2020 | 56430 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2020 | 378 | 0.040 |
Why?
|
| Humans | 17 | 2023 | 744343 | 0.040 |
Why?
|
| Male | 11 | 2020 | 350118 | 0.040 |
Why?
|
| Puberty | 1 | 2020 | 490 | 0.040 |
Why?
|
| Phagocytes | 1 | 2018 | 297 | 0.040 |
Why?
|
| Mutant Proteins | 1 | 2018 | 500 | 0.030 |
Why?
|
| Survival Rate | 1 | 2010 | 12788 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 2124 | 0.030 |
Why?
|
| Female | 10 | 2020 | 380194 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2018 | 809 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2018 | 913 | 0.030 |
Why?
|
| Prognosis | 3 | 2022 | 29063 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6538 | 0.030 |
Why?
|
| Age of Onset | 1 | 2020 | 3271 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2020 | 1538 | 0.030 |
Why?
|
| Adult | 5 | 2020 | 214055 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.030 |
Why?
|
| Myeloablative Agonists | 1 | 2012 | 218 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2023 | 77449 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2019 | 1349 | 0.020 |
Why?
|
| Virus Diseases | 1 | 2017 | 711 | 0.020 |
Why?
|
| Pedigree | 1 | 2018 | 4644 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2012 | 741 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 11524 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2018 | 4204 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2020 | 5867 | 0.020 |
Why?
|
| Biopsy | 1 | 2020 | 6756 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 598 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2023 | 53288 | 0.020 |
Why?
|
| Disease Management | 1 | 2018 | 2459 | 0.020 |
Why?
|
| Neutrophils | 1 | 2020 | 3719 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 3386 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 1607 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 39050 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 4149 | 0.020 |
Why?
|
| Genotype | 1 | 2020 | 12951 | 0.020 |
Why?
|
| Middle Aged | 3 | 2019 | 213383 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10252 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10388 | 0.020 |
Why?
|
| Time Factors | 1 | 2006 | 40075 | 0.020 |
Why?
|
| Disease Progression | 1 | 2020 | 13284 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2018 | 13033 | 0.010 |
Why?
|
| United States | 2 | 2022 | 69872 | 0.010 |
Why?
|
| Graft Survival | 1 | 2012 | 3737 | 0.010 |
Why?
|
| Inflammation | 1 | 2019 | 10638 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 17446 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 10180 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 35421 | 0.010 |
Why?
|